Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy
Top Cited Papers
- 14 November 2019
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (22)
- https://doi.org/10.1172/jci.insight.131347
Abstract
BACKGROUND. IL-33, found in high levels in participants with allergic disorders, is thought to mediate allergic reactions. Etokimab, an anti–IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. METHODS. In this 6-week placebo-controlled phase 2a study, we evaluated the safety and the ability of a single dose of etokimab to desensitize peanut-allergic adults. Participants received either etokimab (n = 15) or blinded placebo (n = 5). Clinical tests included oral food challenges and skin prick tests at days 15 and 45. Blood samples were collected for IgE levels and measurement of ex vivo peanut-stimulated T cell cytokine production. RESULTS. Efficacy measurements for active vs. placebo participants at the day 15 and 45 food challenge (tolerating a cumulative 275 mg of peanut protein, which was the food challenge outcome defined in this paper) demonstrated, respectively, 73% vs. 0% (P = 0.008) to 57% vs. 0% (ns). The etokimab group had fewer adverse events compared with placebo. IL-4, IL-5, IL-9, IL-13, and ST2 levels in CD4+ T cells were reduced in the active vs. placebo arm upon peanut-induced T cell activation (P = 0.036 for IL-13 and IL-9 at day 15), and peanut-specific IgE was reduced in active vs. placebo (P = 0.014 at day 15). CONCLUSION. The phase 2a results suggest etokimab is safe and well tolerated and that a single dose of etokimab could have the potential to desensitize peanut-allergic participants and possibly reduce atopy-related adverse events. TRIAL REGISTRATION. ClinicalTrials.gov NCT02920021. FUNDING. This work was supported by NIH grant R01AI140134, AnaptysBio, the Hartman Vaccine Fund, and the Sean N. Parker Center for Allergy and Asthma Research at Stanford University.Keywords
Funding Information
- AnaptysBio (N/A)
- Sean N. Parker Center for Allergy and Asthma Research at Stanford University (N/A)
This publication has 43 references indexed in Scilit:
- Prevalence of common food allergies in Europe: a systematic review and meta-analysisAllergy, 2014
- Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3)Journal of Allergy and Clinical Immunology, 2014
- Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology–European Academy of Allergy and Clinical Immunology PRACTALL consensus reportJournal of Allergy and Clinical Immunology, 2012
- Interleukin‐33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin‐4 in naïve miceAllergy, 2012
- Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infectionThe Journal of Experimental Medicine, 2012
- Anti‐IL‐33 antibody has a therapeutic effect in a murine model of allergic rhinitisAllergy, 2011
- The role of IL‐33 and its receptor ST2 in human nasal epithelium with allergic rhinitisClinical and Experimental Allergy, 2011
- The Prevalence, Severity, and Distribution of Childhood Food Allergy in the United StatesPediatrics, 2011
- Trends in pediatric emergency department visits for food-induced anaphylaxisJournal of Allergy and Clinical Immunology, 2010
- IL-33 Is Produced by Mast Cells and Regulates IgE-Dependent InflammationPLOS ONE, 2010